Intravenous iron for the treatment of iron deficiency in IBD: the pendulum is swinging.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 24300864.
- Also identified by DOI 10.1038/ajg.2013.400.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Intravenous (IV) iron therapy has been a major asset in the management of refractory iron-deficiency anemia in inflammatory bowel disease (IBD) and other diseases. However, the cost-effectiveness of parenteral substitution as the first-line treatment of this condition in IBD has been questioned. A study published by Reinisch et al. in this issue of the journal fails to show non-inferiority of iron isomaltose 1,000, a novel high-dose IV preparation, compared to oral iron sulfate.
Medical subject headings
- Anemia, Iron-Deficiency
- Disaccharides
- Ferric Compounds
- Inflammatory Bowel Diseases
- Iron